Portola Pharmaceuticals, Inc.

( )
PTLA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 0.48%53.970.9%$1408.01m
JNJJohnson & Johnson -0.05%179.540.7%$1296.44m
BMYBristol-Myers Squibb Co. 0.45%77.591.0%$1212.16m
MRKMerck & Co., Inc. -1.53%92.320.7%$1167.02m
ABBVAbbVie, Inc. -0.92%150.561.9%$1100.30m
LLYEli Lilly & Co. 2.11%313.481.1%$967.28m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.29%142.980.0%$491.89m
AZNAstraZeneca Plc -0.17%66.701.0%$491.50m
NVSNovartis AG 0.01%91.260.2%$259.85m
GSKGlaxoSmithKline Plc -1.23%44.420.2%$257.59m
VERUVeru, Inc. 2.18%12.640.0%$253.71m
HZNPHorizon Therapeutics Plc 2.45%90.595.4%$196.03m
SGENSeagen Inc. 1.46%138.465.7%$185.67m
NVONovo Nordisk A/S 1.30%106.620.1%$182.89m
VTRSViatris, Inc. 1.44%12.010.0%$165.27m

Company Profile

Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California.